NEMO1:NEonatal Seizure Using Medication Off-patent
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
NEMO is a multicentre pan European clinical trial with the aim to develop new treatment
strategies for the treatment of neonatal seizures using the loop diuretic bumetanide. There
is evidence that bumetanide improves GABAergic function of the current standard drug,
phenobarbitone. Bumetanide has been used as a diuretic in term and preterm babies for around
thirty years. This trial should confirm that Bumetanide in addition to standard treatment
will result in better seizures control.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Great Ormond Street Hospital for Children NHS Foundation Trust
Collaborators:
Cork University Hospital Erasmus Medical Center Helsinki University Central Hospital Hôpital Necker-Enfants Malades Karolinska University Hospital Only For Children Pharmaceuticals The Leeds Teaching Hospitals NHS Trust UMC Utrecht University College London Hospitals Uppsala University Hospital